The design of the current custom melanoma ctDNA panel was limited to key melanoma-associated gene mutations, but still had a theoretical coverage of ~81% of skin cutaneous melanoma [66% based on skin cutaneous melanoma TCGA database (45, 46) plus (15-60%) triple wild type melanoma with TERT promoter mutations (33, 38–40, 43, 44)]. This evidence concerns the gene TERT and melanoma.